JP6305345B2 - 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 - Google Patents

鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 Download PDF

Info

Publication number
JP6305345B2
JP6305345B2 JP2014546468A JP2014546468A JP6305345B2 JP 6305345 B2 JP6305345 B2 JP 6305345B2 JP 2014546468 A JP2014546468 A JP 2014546468A JP 2014546468 A JP2014546468 A JP 2014546468A JP 6305345 B2 JP6305345 B2 JP 6305345B2
Authority
JP
Japan
Prior art keywords
lipocalin mutein
hepcidin
iron
lipocalin
mutein
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2014546468A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015501822A (ja
JP2015501822A5 (enExample
Inventor
アンドレアス ホールバウム
アンドレアス ホールバウム
ヘンドリック ジル
ヘンドリック ジル
ステファン トレントマン
ステファン トレントマン
ローレント オドリ
ローレント オドリ
アンドレア アレアシュドルファー
アンドレア アレアシュドルファー
Original Assignee
ピエリス ファーマシューティカルズ ゲーエムベーハー
ピエリス ファーマシューティカルズ ゲーエムベーハー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ピエリス ファーマシューティカルズ ゲーエムベーハー, ピエリス ファーマシューティカルズ ゲーエムベーハー filed Critical ピエリス ファーマシューティカルズ ゲーエムベーハー
Publication of JP2015501822A publication Critical patent/JP2015501822A/ja
Publication of JP2015501822A5 publication Critical patent/JP2015501822A5/ja
Application granted granted Critical
Publication of JP6305345B2 publication Critical patent/JP6305345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
JP2014546468A 2011-12-12 2012-12-12 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法 Expired - Fee Related JP6305345B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201161569501P 2011-12-12 2011-12-12
US61/569,501 2011-12-12
US201261599152P 2012-02-15 2012-02-15
US61/599,152 2012-02-15
PCT/EP2012/075135 WO2013087654A2 (en) 2011-12-12 2012-12-12 Methods for preventing or treating disorders by increasing bioavailability of iron and related pharmaceutical formulation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018039343A Division JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Publications (3)

Publication Number Publication Date
JP2015501822A JP2015501822A (ja) 2015-01-19
JP2015501822A5 JP2015501822A5 (enExample) 2016-02-04
JP6305345B2 true JP6305345B2 (ja) 2018-04-04

Family

ID=47552958

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014546468A Expired - Fee Related JP6305345B2 (ja) 2011-12-12 2012-12-12 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
JP2018039343A Pending JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018039343A Pending JP2018118980A (ja) 2011-12-12 2018-03-06 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法

Country Status (9)

Country Link
US (3) US9610356B2 (enExample)
EP (2) EP2791684B1 (enExample)
JP (2) JP6305345B2 (enExample)
CN (1) CN103998937A (enExample)
AU (1) AU2012350654C1 (enExample)
CA (1) CA2858959A1 (enExample)
DK (1) DK2791684T3 (enExample)
SG (2) SG10201604574UA (enExample)
WO (1) WO2013087654A2 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105168209A (zh) * 2015-09-21 2015-12-23 浙江大学 HDAC1抑制剂在制备调控hepcidin表达药物中的应用
CN105726543A (zh) * 2016-02-22 2016-07-06 浙江大学 腺嘌呤在制备调控hepcidin表达药物中的应用
JP6432962B2 (ja) 2016-03-29 2018-12-05 株式会社国際電気通信基礎技術研究所 腎機能低下、慢性腎疾患及び腎不全からなる群から選択される少なくとも一種の疾患を予防、又は治療するための有効成分の候補物質のスクリーニング方法
CN109641954A (zh) * 2016-08-29 2019-04-16 里珍纳龙药品有限公司 抗-gremlin-1(grem1)抗体及其用于治疗肺动脉高血压的使用方法
AU2020253034A1 (en) 2019-03-29 2021-08-19 Pieris Pharmaceuticals Gmbh Inhaled administration of lipocalin muteins
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
KR20230012539A (ko) 2020-05-13 2023-01-26 디스크 메디슨, 인크. 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체
WO2022098812A1 (en) 2020-11-04 2022-05-12 Keros Therapeutics, Inc. Methods of treating iron overload
JP2023117892A (ja) * 2022-02-14 2023-08-24 公益財団法人 鷹揚郷 ヘプシジン結合ペプチド

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19926068C1 (de) 1999-06-08 2001-01-11 Arne Skerra Muteine des Bilin-Bindungsproteins
US7118915B2 (en) 2001-09-27 2006-10-10 Pieris Proteolab Ag Muteins of apolipoprotein D
WO2003029462A1 (en) 2001-09-27 2003-04-10 Pieris Proteolab Ag Muteins of human neutrophil gelatinase-associated lipocalin and related proteins
WO2005019255A1 (en) 2003-08-25 2005-03-03 Pieris Proteolab Ag Muteins of tear lipocalin
EP1996613B1 (en) * 2006-03-20 2014-04-30 Technische Universität München Muteins of tear lipocalin with affinity for the t-cell coreceptor cd4
JP5410971B2 (ja) 2006-07-21 2014-02-05 アムジエン・インコーポレーテツド サンプル中のヘプシジンを検出および／または測定する方法
TW201206954A (en) * 2007-02-02 2012-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
CL2008003190A1 (es) 2007-11-02 2009-09-04 Lilly Co Eli Anticuerpo que se enlaza selectivamente a hepcidina-25 humana madura; polinucleotido codificante, vector y celula huesped que lo comprende; uso medico para tratar la anemia, incrementar nivel de hierro, conteo de rediculocito, celulas rojas, hemoglobina, o hematocritos; proceso de produccion; composicion farmaceutica.
EP2247618B1 (en) 2008-01-25 2014-06-11 Amgen, Inc Ferroportin antibodies and methods of use
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
DK2328931T3 (da) 2008-08-06 2013-09-30 Lilly Co Eli Selektive anti-hepcidin-25-antistoffer og anvendelser deraf
EP2330897A4 (en) * 2008-09-18 2013-11-27 Univ Columbia NGAL-BINDING SIDEROPHORES AND THEIR USE FOR THE TREATMENT OF IRON DEFICIENCY AND IRON SURPLUS
SG10201609416XA (en) * 2009-03-25 2016-12-29 Genentech Inc NOVEL ANTI-α5ß1 ANTIBODIES AND USES THEREOF
WO2011143232A1 (en) * 2010-05-10 2011-11-17 Westerman Mark E Markers for acute kidney injury
JP2013529907A (ja) * 2010-05-24 2013-07-25 ザ トラスティーズ オブ コロンビア ユニヴァーシティ イン ザ シティ オブ ニューヨーク Ｎｇａｌタンパク質変異体及びその使用
AU2011290751B2 (en) 2010-08-16 2015-08-13 Pieris Ag Binding proteins for Hepcidin

Also Published As

Publication number Publication date
JP2018118980A (ja) 2018-08-02
SG10201604574UA (en) 2016-07-28
JP2015501822A (ja) 2015-01-19
AU2012350654A1 (en) 2014-07-03
CN103998937A (zh) 2014-08-20
US20180311311A1 (en) 2018-11-01
US9950034B2 (en) 2018-04-24
EP2791684A2 (en) 2014-10-22
AU2012350654B2 (en) 2017-12-14
US20140323389A1 (en) 2014-10-30
AU2012350654C1 (en) 2018-05-10
DK2791684T3 (da) 2017-11-27
EP3309555A3 (en) 2018-05-30
US9610356B2 (en) 2017-04-04
US20170224770A1 (en) 2017-08-10
SG11201402996WA (en) 2014-07-30
WO2013087654A2 (en) 2013-06-20
EP2791684B1 (en) 2017-08-23
CA2858959A1 (en) 2013-06-20
WO2013087654A3 (en) 2013-09-12
EP3309555A2 (en) 2018-04-18

Similar Documents

Publication Publication Date Title
JP6305345B2 (ja) 鉄および関連する薬学的製剤のバイオアベイラビリティを増加させることによる障害の予防または治療方法
Benjamin et al. Pharmacokinetics of peptide–Fc fusion proteins
Vittori et al. Erythropoietin and derivatives: Potential beneficial effects on the brain
Sleep et al. Albumin as a versatile platform for drug half-life extension
JP6505288B2 (ja) 補体ｃ５を標的とする治療薬の血清半減期を増加させるための組成物及び方法
Kim et al. Albumin turnover: FcRn-mediated recycling saves as much albumin from degradation as the liver produces
KR101428344B1 (ko) 변이체 액티빈 수용체 폴리펩타이드 및 이의 용도
JP7303629B2 (ja) 長時間作用型ｆｇｆ２１融合タンパク質およびそれを含む医薬組成物
JP7500662B2 (ja) 抗第ＸＩ／ＸＩａ因子抗体による処置法
JP2015501822A5 (enExample)
Kaufman et al. Molecular approaches for improved clotting factors for hemophilia
Schmid et al. Investigational therapies for renal disease-induced anemia
JP2013529907A (ja) Ｎｇａｌタンパク質変異体及びその使用
TW201439118A (zh) Ｂｍｐ－６抗體
EP3642338A1 (en) Fusion protein with half-life extending polypeptide
Zhao et al. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice
JP2021176875A (ja) ポリエチレングリコール（ｐｅｇ）−インターロイキン１１（ｉｌ−１１）コンジュゲートを生成するための反応中間体、および、ｐｅｇ−ｉｌ−１１コンジュゲートを精製する方法
KR20200067158A (ko) 인간 혈청 알부민 변이체 및 이의 용도
Alexander et al. Abnormal immune complex processing and spontaneous glomerulonephritis in complement factor H-deficient mice with human complement receptor 1 on erythrocytes
US20140348848A1 (en) Anti-il-1beta (interleukin-1beta) antibody-based prophylactic therapy to prevent complications leading to vaso-occlusion in sickle cell disease
CN107921103A (zh) 涉及长半衰期凝血复合物的方法和组合物
JP7094223B2 (ja) 病的な筋肉減少および筋力低下の処置のためのｎｏｐｅ
WO2023098637A1 (zh) 预防和/或治疗血栓栓塞性疾病的方法
Gkouvatsos Insights on the role of the protein hemojuvelin in the maintenance of systemic iron homeostasis
WO2013068590A1 (en) Lipocalin muteins as vegf antagonists for use in treating diseases caused or promoted by increased vascularization

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20141016

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20150619

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151211

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20151211

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20161130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20170228

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170712

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20180205

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20180306

R150 Certificate of patent or registration of utility model

Ref document number: 6305345

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

LAPS Cancellation because of no payment of annual fees